Hydroxyurea

SKU: orb1310395

Description

Hydroxyurea

Research Area

Cell Biology, Infectious Disease & Virology, Molecular Biology, Protein Biochemistry

Key Properties

• CAS Number: 127-07-1
• MW: 76.05
• Purity: 99.85%
• Formula: CH₄N₂O₂
• SMILES: NC(=O)NO
• Target: HIV Protease,Virus Protease,Apoptosis,Autophagy,DNA/RNA Synthesis
• Solubility: H2O:55 mg/mL (723.21 mM);DMSO:255 mg/mL (3353.06 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:5 mg/mL (65.75 mM)

Bioactivity

• In Vivo:
  Hydroxyurea treatment consistently decreases white blood cell (WBC) and absolute neutrophil count (ANC), yet does not enhance anemia over a 17-week period. At a dosage of 50 mg/kg, hydroxyurea effectively lowers WBC and ANC without ameliorating anemia in comparison to Vehicle-treated sickle cell mice.
• In Vitro:
  hydroxyurea can inhibit HIV-1 replication. In vitro experiments have shown tha the 90% inhibitory concentration (IC90) of hydroxyurea for laboratory strains of HIV-1 in activated PBMC is 0.4 mM. Hydroxyurea was also found to be synergistic wit the nucleoside reverse transcriptase inhibitor didanosine and to inhibit HIV-1 replication in activated PBMC; this Inhibition may be due to a reduction in deoxynucleoside triphosphate pool sizes. Hydroxyurea has been shown to sensitize didanosine-resistant mutant [1. ydroxyurea has demonstrated activity in the treatment of sickle cell anemia by increasin the production of fetal hemoglobin, which reduces hemolysis in patients with this disease. Hydroxyurea exerts its cytostatic effect through Inhibition of ribonucleotide reductase—the rate-limiting enzyme responsible fo the conversion of ribonucleotides to deoxyribonucleotides, which are essential for DNA synthesis. As a result, cellular division is arrested in the S phas.
• Cell Research:
  Erythroid cells obtained from peripheral blood o the same patients(Thirteen β-Thal/HbE patients are treated with hydroxyurea orally for 2 years at a starting dose of 5 mg/kg/day for 5 days/week with escalation to a maximum of 10 mg/kg/day) 1 year after they had stopped hydroxyurea treatment are treated with hydroxyurea in vitro Treatment of cells performs in Primary culture with 30 μM hydroxyurea for 96 hours.(Only for Reference)

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Autophagy, Apoptosis, DNA Synthesis, DNA/RNA Synthesis, DNASynthesis, Inhibitor, inhibit, nsc32065, nci-c04831, HIVProtease, HIV, HIV Protease, Hydroxycarbamide, Hydroxyurea, Human immunodeficiency virus, RNASynthesis, RNA Synthesis, ribonucleoside diphosphate reductase

Compound Identifiers

PubChem CID

3657